Tamoxifen and Risk of Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Research output: Contribution to journal › Article
To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers.
|Research areas and keywords||
Subject classification (UKÄ) – MANDATORY
|Journal||Journal of Clinical Oncology|
|Publication status||Published - 2013|